GlassScriptPhysician profile
Robert P Burke
NPI 1629044987
$3,548.43
in general payments reported to CMS, 2019-2025
36 companies · $537 in 2025
The $537 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $239 · 2021: $330 · 2022: $264 · 2023: $1,342 · 2024: $632 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $496.21 | 2022-2025 | Rexulti |
| Abbvie INC. | $438.93 | 2021-2025 | Vraylar, Mavyret, Ubrelvy |
| Glaxosmithkline, LLC. | $311.81 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $274.57 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.11 | 2019-2025 | Trulance, Xifaxan |
| Indivior INC. | $205.71 | 2019-2025 | Sublocade |
| Braeburn INC. | $191.28 | 2023-2025 | Brixadi |
| Amarin Pharma, INC. | $165.20 | 2019-2020 | |
| Gilead Sciences, INC. | $162.73 | 2019-2024 | |
| Pfizer INC. | $147.28 | 2022-2025 | |
| Baxter Healthcare | $104.48 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Lundbeck LLC | $85.09 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $68.62 | 2023 | |
| Lilly USA, LLC | $68.40 | 2023-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $67.72 | 2024 | Voquezna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $54.34 | 2022-2025 | Spravato |
| Abbott Laboratories | $52.46 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Vertex Pharmaceuticals Incorporated | $40.83 | 2024 | |
| Novo Nordisk INC | $39.57 | 2024-2025 | Wegovy, Rybelsus |
| Orexo US, INC. | $36.37 | 2022-2023 | Zubsolv |
| Biohaven Pharmaceuticals, INC. | $31.70 | 2021 | |
| Bausch Health US, LLC | $31.01 | 2021 | |
| Dexcom, INC. | $27.03 | 2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $20.60 | 2020 | |
| Astellas Pharma US INC | $19.78 | 2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $19.26 | 2019 | |
| Merck Sharp & Dohme LLC | $18.60 | 2022 | |
| Bardy Diagnostics, INC. | $18.40 | 2022 | |
| Shield Therapeutics INC | $17.55 | 2025 | |
| Genentech USA, INC. | $17.35 | 2021 | |
| Ibsa Pharma INC. | $17.23 | 2025 | Licart, Tirosint, Flector |
| Axsome Therapeutics, INC. | $16.19 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $16.11 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.30 | 2025 | Jardiance |
| International Rehabilitative Sciences, INC | $14.39 | 2023 | Rs 4i Plus Sequential Stimulator |
| Amgen INC. | $14.22 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.